Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer

Table 2 Association of tumor markers with benign gallbladder disease and gallbladder cancer

All parameters	Benign, n = 120	Carcinoma, n = 80	P value
CA 19-9 in U/mL	3.1 (1.4-19.4)	112.9 (23.3-318.8)	< 0.001
CA 19-9, n (%)
Normal	108 (90.0)	23 (28.7)	< 0.001
Elevated	12 (10.0)	57 (71.3)
CA 125 in U/mL	8.6 (3.1-15.1)	24.5 (12.0-53.3)	< 0.001
CA 125, n (%)
Normal	112 (93.3)	49 (61.3)	< 0.001
Elevated	8 (6.7)	31 (38.8)
CEA in µg/L	2.3 (1.2-3.1)	3.1 (1.8-4.5)	< 0.003
CEA, n (%)
Normal	114 (94)	60 (75)	< 0.003
Elevated	6 (5.9)	20 (25)
CA 242 in U/mL	2.8 (1.5-9.8)	55.5 (32.7-96.5)	< 0.001
CA 242, n (%)
Normal	108 (90.0)	11 (13.7)	< 0.001
Elevated	12 (10.0)	69 (86.3)

Data shown as median (interquartile range). Qualitative data between benign and carcinoma groups were analyzed using Mann-Whitney U-test and quantitative data were compared with the χ² test. CA 19-9: Carbohydrate antigen 19-9; CA 125: Carbohydrate antigen 125; CA 242: Carbohydrate antigen 242; CEA: Carcinoembryonic antigen.